Benjamin F. Edwards & Company reduced its stake in Amgen, Inc. (NASDAQ:AMGN) by 1.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,317 shares of the medical research company’s stock after selling 56 shares during the period. Benjamin F. Edwards & Company’s holdings in Amgen were worth $863,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Proficio Capital Partners purchased a new position in shares of Amgen during the fourth quarter valued at $28,000. Renaissance Investment Group purchased a new position in shares of Amgen during the fourth quarter valued at $242,000. Curbstone Financial Management purchased a new position in shares of Amgen during the fourth quarter valued at $440,000. Reynolds Capital Management raised its position in shares of Amgen by 86.7% in the fourth quarter. Reynolds Capital Management now owns 2,800 shares of the medical research company’s stock valued at $455,000 after buying an additional 1,300 shares during the period. Finally, EisnerAmper Wealth Management raised its position in shares of Amgen by 9.2% in the fourth quarter. EisnerAmper Wealth Management now owns 3,174 shares of the medical research company’s stock valued at $515,000 after buying an additional 267 shares during the period.

Amgen, Inc. (NASDAQ:AMGN) traded up 2.36% during midday trading on Friday, hitting $151.85. The stock had a trading volume of 5,131,208 shares. The stock’s 50 day moving average price is $156.56 and its 200-day moving average price is $156.97. The company has a market cap of $114.54 billion and a PE ratio of 18.13. Amgen, Inc. has a 52 week low of $130.09 and a 52 week high of $181.81.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, January 28th. The medical research company reported $2.61 earnings per share for the quarter, beating analysts’ consensus estimates of $2.29 by $0.32. The company had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5.53 billion. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.16 earnings per share. Equities research analysts predict that Amgen, Inc. will post $10.08 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 16th will be issued a dividend of $1.00 per share. This is a positive change from Amgen’s previous quarterly dividend of $0.47. This represents a $4.00 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend is Thursday, February 11th.

Several research analysts recently weighed in on AMGN shares. Morgan Stanley increased their target price on Amgen to $160.00 in a research report on Thursday, October 29th. Goldman Sachs raised their price objective on Amgen from $213.00 to $218.00 in a research report on Friday. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $168.23 price objective on the stock in a research report on Friday, November 6th. Piper Jaffray reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research report on Friday, January 8th. Finally, Jefferies Group reissued a “buy” rating on shares of Amgen in a research report on Saturday, January 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $186.30.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

12 Month Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.